MONDAY, NOVEMBER 20, 2017

NanoViricides signs agreement with PHE

NanoViricides, Inc., a West Haven, Connecticut-based development stage company, announced a confidential disclosure agreement on Monday with Public Health England, an executive agency of the U.K. Department of Health. Read More »

Novavax initiates Phase I trial of H7N9 influenza vaccine candidate

Novavax, Inc., a Rockville, Maryland-based clinical-stage biopharmaceutical company, announced on Monday that enrollment began in a Phase I clinical trial of the company's vaccine candidate against influenza A H7N9. Read More »

WHO calls for emergency committee regarding MERS-CoV

World Health Organization Director-General Margaret Chan announced on Friday that the WHO has called for an emergency committee to discuss the ongoing threat of MERS-CoV. Read More »

China reports another confirmed case of avian flu to WHO

H7N9 Virus Read More »

Lions Club International partners with GAVI Alliance to fight measles

Lions Club International, a service club organization, and the GAVI Alliance, a public-private partnership, announced a new collaboration on Monday meant to protect tens of millions of children in the poorest countries against measles. Read More »

Inovio Pharmaceuticals' H7N9 vaccine protects 100 percent of animals in study

Inovio Pharmaceuticals, Inc., a Blue Bell, Pennsylvania-based vaccine developer, announced on Monday that its H7N9 influenza DNA vaccine protected 100 percent of vaccinated animals against sickness and death in a preclinical study. Read More »

CDC Influenza kit achieves FDA clearance

Quanta BioSciences, Inc., announced on Monday that its CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel Kit has received FDA clearance. Read More »

Assays studied for TB identification and drug resistance detection

Tuberculosis Read More »

NIH scientists look into pandemic potential of H7 influenza viruses

Scientists recently evaluated past outbreaks of H7 subtype influenza viruses to determine the pandemic potential of the novel H7N9 avian influenza virus infecting humans in China, the National Institutes of Health said on Tuesday. Read More »

Sorrento Therapeutics partners with university to develop antibodies

Sorrento Therapeutics, Inc., a San Diego-based development-stage biopharmaceutical company, announced an option and license agreement on Tuesday with the Israel-based B.G. Negev Technologies and Applications, Ltd., to develop anti-hepatitis C virus antibodies. Read More »

Polio scare in Israel starts vaccine campaign

Polio Read More »

New vaccine may protect bird species from West Nile virus

West Nile virus Read More »

Global Fund signs $100 million grant agreement with Namibia

The Global Fund to Fight AIDS, Tuberculosis and Malaria signed grant agreements on Tuesday with Namibia for $91.6 million to support the national response to HIV and $8.5 million for malaria programs. Read More »

Novartis announces agreement with Biological E for fever vaccines

Novartis, a Basel, Switzerland-based healthcare solutions company, announced a development and licensing agreement on Monday with Biological E Limited, an India-based biopharmaceutical company, to deliver vaccines against typhoid and paratyphoid fevers. Read More »

GenScript aids Novavax's H7N9 vaccine development

GenScript announced on Monday that it has aided Novavax, Inc., in the development of a H7N9 avian influenza vaccine candidate by providing Rush Gene Services. Read More »

New refrigeration technology provides vaccines for developing countries

Global Good and AUCMA announced on Tuesday that they will partner to manufacture and distribute AUCMA's refrigeration device to help end mortality by vaccine-preventable diseases in underserved regions in the developing world. Read More »

H7N9 has unusual traits that could lead to a pandemic

H7N9 Virus Read More »

Euromonitor releases report on Argentinian home insecticides

Euromonitor International, a strategic research company, recently published a research report called Home Insecticides in Argentina, which details the size and shape of the insecticide market in the dengue-endemic country. Read More »

Dr. Robin Weiss appointed chair of IAVI's Scientific Advisory Committee

The International AIDS Vaccine Initiative announced on Tuesday that it has appointed Dr. Robin Weiss as Chair of the Scientific Advisory Committee. Read More »

Pfizer pneumonia vaccine Prevenar 13 gains European approval

Pfizer, Inc., announced on Wednesday that its pneumococcal conjugate vaccine Prevenar 13 was approved in Europe for adults aged 18 to 49 for the treatment of disease caused by vaccine-type Streptococcus pneumonia. Read More »